Nkarta Inc - Asset Resilience Ratio
Nkarta Inc (NKTX) has an Asset Resilience Ratio of 58.55% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read NKTX current and long-term liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Nkarta Inc's Asset Resilience Ratio has changed over time. See NKTX total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Nkarta Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Nkarta Inc stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $236.65 Million | 58.55% |
| Total Liquid Assets | $236.65 Million | 58.55% |
Asset Resilience Insights
- Very High Liquidity: Nkarta Inc maintains exceptional liquid asset reserves at 58.55% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Nkarta Inc Industry Peers by Asset Resilience Ratio
Compare Nkarta Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Nkarta Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Nkarta Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 58.55% | $236.65 Million | $404.21 Million | +10.76pp |
| 2024-12-31 | 47.78% | $239.48 Million | $501.20 Million | -9.53pp |
| 2023-12-31 | 57.31% | $217.15 Million | $378.88 Million | -9.22pp |
| 2022-12-31 | 66.53% | $314.65 Million | $472.94 Million | +1.81pp |
| 2021-12-31 | 64.72% | $177.27 Million | $273.90 Million | +0.09pp |
| 2020-12-31 | 64.63% | $218.22 Million | $337.65 Million | +30.79pp |
| 2019-12-31 | 33.84% | $16.38 Million | $48.41 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $9.61 Million | -- |
About Nkarta Inc
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myo… Read more